Package 0006-3074-02

{"route": ["ORAL"], "spl_id": "21d93204-5c90-4b70-aec4-f7e60b197fac", "openfda": {"nui": ["N0000191256", "N0000190113", "N0000182638", "N0000182639", "N0000190114"], "unii": ["632L571YDK", "8YE81R1X1J"], "rxcui": ["1734636", "1734642"], "spl_set_id": ["164dc02a-9180-426a-b8b5-04ab39d2bbd4"], "pharm_class_epc": ["Hepatitis C Virus NS5A Inhibitor [EPC]", "Hepatitis C Virus NS3/4A Protease Inhibitor [EPC]"], "pharm_class_moa": ["Breast Cancer Resistance Protein Inhibitors [MoA]", "HCV NS3/4A Protease Inhibitors [MoA]", "Cytochrome P450 3A Inhibitors [MoA]"], "manufacturer_name": ["Merck Sharp & Dohme LLC"], "is_original_packager": [true]}, "finished": true, "packaging": [{"sample": false, "description": "2 DOSE PACK in 1 CARTON (0006-3074-02)  / 14 TABLET, FILM COATED in 1 DOSE PACK (0006-3074-01)", "package_ndc": "0006-3074-02", "marketing_start_date": "20160128"}], "brand_name": "ZEPATIER", "product_id": "0006-3074_21d93204-5c90-4b70-aec4-f7e60b197fac", "dosage_form": "TABLET, FILM COATED", "pharm_class": ["Breast Cancer Resistance Protein Inhibitors [MoA]", "Breast Cancer Resistance Protein Inhibitors [MoA]", "Cytochrome P450 3A Inhibitors [MoA]", "HCV NS3/4A Protease Inhibitors [MoA]", "Hepatitis C Virus NS3/4A Protease Inhibitor [EPC]", "Hepatitis C Virus NS5A Inhibitor [EPC]"], "product_ndc": "0006-3074", "generic_name": "elbasvir and grazoprevir", "labeler_name": "Merck Sharp & Dohme LLC", "product_type": "HUMAN PRESCRIPTION DRUG", "brand_name_base": "ZEPATIER", "active_ingredients": [{"name": "ELBASVIR", "strength": "50 mg/1"}, {"name": "GRAZOPREVIR ANHYDROUS", "strength": "100 mg/1"}], "application_number": "NDA208261", "marketing_category": "NDA", "marketing_start_date": "20160128", "listing_expiration_date": "20261231"}